Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: A randomized, placebo-controlled trial

Multiple Sclerosis

Volumn 13, Issue 3, 2007, Pages 376-385

  Lovera, Jesus ^a,b   Bagert, B ^d   Smoot, K ^b   Morris, C D ^c   Frank, R ^b   Bogardus, K ^b   Wild, K ^b   Oken, B ^b   Whitham, R ^a,b   Bourdette, D ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cognition; Double blind method; Gibkgo biloba; Multiple sclerosis; Neuropsychological tests; Placebos; Quality of life; Randomized controlled trials

Indexed keywords

GINKGO BILOBA EXTRACT; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PERSONALITY TEST; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; THROMBOCYTE FUNCTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ATTENTION; CAPSULES; COGNITION; FEMALE; GINKGO BILOBA; HUMANS; LEARNING; MALE; MEMORY; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT SELECTION; PHYTOTHERAPY; PLACEBOS; PLANT EXTRACTS; REPRODUCIBILITY OF RESULTS; VERBAL LEARNING;

EID: 34248140642     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506071213     Document Type: Article

References (32)

1. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685-91.
2. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001; 58: 1602-606.
3. DeFeudis FV. Ginkgo biloba extract (EGb 761): pharmacological activities and clinical applications. Elsevier, 1991: 401.
4. Nathan P. Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology? Med Hypotheses 2000; 55: 491-93.
5. Huang SH, Duke RK, Chebib M, Sasaki K, Wada K, Johnston GA. Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2gamma2L, GABAA receptors. Eur J Pharmacol 2004; 494: 131-38.
6. Koltai M, Hosford D, Guinot P, Esarm A, Braquet P. Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical implications (Part 1). Drugs 1991; 42: 9-29.
7. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 2003; 60: 1779?92.
8. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55: 1409-15.
9. Yadav V, Shynto L, Morris C, Senders A, Baldauf-Wagner S, Bourdette D. Use and self reported benefit of complementary and alternative medicine (CAM) among multiple sclerosis patients. Int J MS Care 2000; 8: 5-10.
10. Brochet B, Guinot P, Orgogozo JM, Confavreux C, Rumbach L, Lavergne V. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in Multiple Sclerosis. J Neurol Neurosurg Psychiatry 199S; 58: 360-62.
11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-17.
12. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Multiple sclerosis functional composite administration and scoring manual [online]. Retrieved from http://www.nationalmssociety.org/ %5Cpdf%5Cresearch%5CMSFCn̄ual∠d∀rms.pdf
13. Lezak MD, Howieson DB, Loring DW, Hannay J, Fischer JS. Neuropsychological assessment, fourth edition. Oxford University Press, 2004: 519-20.
14. Boringa JB, Lazeron RH, Reuling IE, Ader HJ, Pfennings L, Lindeboom J et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler 2001; 7: 263-67.
15. Ball KK, Roenker DL. UFOV: useful Peld of view. The Psychological Corporation, Harcourt Brace & Company, 1998.
16. Oken B, Flegal K, Zaidel D, Kishiyama S, Lovera J, Bagert B et al. Cognition and fatigue in multiple sclerosis: potential impact of medications with CNS side effects. J Rehabil Res 2006; 43: 83-90.
17. Spreen O, Strauss E. A compendium of neuropsychological tests: administration, nonns, and commentary, second edition. Oxford University Press, 1998: 736.
18. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999; 5: 251-59.
19. Sullivan MJ, Edgley K, Dehoux E. A survey of multiple sclerosis. Part 1: perceived cognitive problems and compensatory strategy use. Can J Rehabil 1990; 4: 99?105.
20. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
21. Delis D, Jramer J, Kaplan E, Ober BA. California Verbal Learning Test, second edition; adult version manual. The Psychological Corporation, 2000: 287.
22. Elsabagh S, Hartley DE, File SE. Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba. J Psychopharmacol 2005; 19: 173-81.
23. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46: 676-80.
24. Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63: 1579-85.
25. Mix JA, Crews WD, Jr. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 2002; 17: 267-77.
26. Fong KC, Kinnear PE. Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion. Postgrad Med J 2003; 79: 531-32.
27. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997; 336: 1108.
28. Miller LG, Freeman B. Possible subdural hematoma associated with Ginkgo biloba. J Herb Phatmacother 2002; 2: 57-63.
29. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46: 1775-76.
30. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998; 352: 36.
31. Bal Dit Sollier C, Caplain H, Drouct L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol 2003; 25: 251-53.
32. Kohler S, Funk P, Kieser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis 2004; 15: 303-309.